The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•6 May 2026•

1 min read

BriaCell Receives FDA Clearance for Bria-BRES+ Breast Cancer Clinical Study

Key Facts

1BriaCell received FDA clearance to initiate a Phase 1/2a clinical study for its Bria-BRES+ immunotherapy in metastatic breast cancer.

BriaCell Therapeutics Corp. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Bria-BRES+. This clearance allows the company to initiate a Phase 1/2a clinical study targeting metastatic breast cancer with its next-generation personalized immunotherapy. The treatment is designed to enhance clinical efficacy through additional immune-activating components integrated into its cell-based platform. This regulatory milestone is a significant step forward for the micro-cap biotech firm in its clinical development pipeline. The study will focus on evaluating the safety and preliminary efficacy of the immunotherapy in patients with advanced stages of the disease. Investors view this as a positive development, marking the transition of Bria-BRES+ into formal clinical evaluation.

Sources: